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Abstract
Purpose: The inflammatory response has been associated with the pathogenesis of Alzheimer’s disease (AD). The
purpose of this study is to determine whether the rs1143627 polymorphism of the interleukin-1 beta (IL-1β) gene
moderates functional magnetic resonance imaging (fMRI)-measured brain regional activity in amnestic mild
cognitive impairment (aMCI).
Methods: Eighty older participants (47 with aMCI and 33 healthy controls) were recruited for this study. All of the
participants were genotyped for variant rs1143627 in the IL1B gene and were scanned using resting-state fMRI.
Brain activity was assessed by amplitude of low-frequency fluctuation (ALFF).
Results: aMCI patients had abnormal ALFF in many brain regions, including decreases in the inferior frontal gyrus,
the superior temporal lobe and the middle temporal lobe, and increases in the occipital cortex (calcarine), parietal
cortex (Pcu) and cerebellar cortex. The regions associated with an interaction of group X genotypes of
rs1143627 C/T were the parietal cortex (left Pcu), frontal cortex (left superior, middle, and medial gyrus, right
anterior cingulum), occipital cortex (left middle lobe, left cuneus) and the bilateral posterior lobes of the cerebellum.
Regarding the behavioral significance, there were significant correlations between ALFF in different regions of the
brain and with the cognitive scores of each genotype group.
Conclusions: The present study provided evidence that aMCI patients had abnormal ALFF in many brain regions.
Specifically, the rs1143627 C/T polymorphism of the IL1B gene may modulate regional spontaneous brain activity in
aMCI patients.
Keywords: Amnestic mild cognitive impairment, Functional magnetic resonance imaging, Amplitude of
low-frequency fluctuation, Interleukin-1 beta, Cognition
Background
Alzheimer’s disease (AD) is the most common form of
dementia worldwide. It is characterized by two micro-
scopic neuropathologic hallmarks - senile plaques com-
posed of amyloid beta (Aβ) and neurofibrillary tangles
composed of hyperphosphorylated tau. Mild cognitive
impairment (MCI) is considered as an intermediate clin-
ical state between normal aging and dementia [1].
According to the impaired domains of cognitive func-
tion, MCI can be divided into amnestic mild cognitive
impairment (aMCI) and nonamnestic MCI [1]. aMCI is
commonly regarded as the prodromal phase of AD, with
10 times the annual conversion rate of normal aging [2].
As research of reliable biomarkers of AD advances,
brain Aβ-plaque deposition and neurodegeneration have
been labeled as the biomarker categories in AD [3].
However, the use of a more extensive biomarker profile,
rather than any single measure, may help improve the
sensitivity and selectivity of predicting AD earlier [4]. In
addition to senile plaques and neurofibrillary tangles, the
Neuroinflammation Working Group has reached a
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consensus that inflammation is involved in the patho-
genesis of AD [5]. Biomarkers, such as cytokines, have
already been assessed [6,7]. The proinflammatory cyto-
kine interleukin-1 beta (IL-1β) is a mental component in
the inflammatory pathway and is overexpressed in the
brain of AD patients. The gene for IL1B maps to
chromosome 2q14. Several polymorphisms of this gene
have been recognized [8]. Among these polymorphisms,
the −31 T > C (rs1143627) polymorphism in the pro-
moter region affects IL1B gene expression particularly.
Functional neuroimaging techniques, which have been
utilized in the study of AD/MCI, mainly include single-
photon emission computed tomography (SPECT), posi-
tron emission tomography (PET) and blood oxygenation
level-dependent (BOLD) functional magnetic resonance
imaging (fMRI). Resting-state fMRI has been developed
as a new branch of this field. Compared with SPECT/
PET, resting-state fMRI has an advantage in that there is
no radiation exposure. Biswal and colleagues have
demonstrated that spontaneous low-frequency (typically
0.01 to 0.08 Hz) fluctuations of the human brain, mea-
sured by resting state fMRI, are physiologically meaning-
ful [9]. An approach to measure the amplitude of low-
frequency fluctuation (ALFF) of BOLD signals in early
AD has been developed to explore regional neural func-
tion by Zang and colleagues [10]. To date, ALFF has
been widely applied to the study of different brain disor-
ders, including epilepsy [11], schizophrenia [12,13], drug
addiction [14], posttraumatic stress disorder (PTSD)
[15], attention deficit hyperactivity disorder (ADHD)
[16,17], multiple sclerosis (MS) [18], and aMCI [19].
This study aimed to determine whether rs1143627 mod-
erates fMRI-measured brain regional activity in aMCI.
Methods
Study participants
A total of 47 aMCI patients and 33 healthy controls
were recruited from the Affiliated Zhongda Hospital of
Southeast University and communities in Nanjing,
China. All of the participants, who were Han Chinese
and right-handed, were interviewed by two trained se-
nior neurologists. This study was approved by the
Southeast University Ethics Committee and informed
consent was obtained from all of the participants.
A diagnosis of aMCI, including single domain (the im-
pairment involves only the memory domain) and mul-
tiple domain (impairment in the memory domain plus
impairments in at least one other cognitive domain),
was made following the recommendations of Petersen
[20] and others [21], including (1) a subjective memory
complaint, preferably corroborated by an informant, (2)
an objective memory impairment, such as a score of less
than or equal to 1.5 SD of age-adjusted and education-
adjusted norms on the 20-min delayed recall of auditory
verbal learning test (AVLT) (the cutoff was ≤4 correct
responses on 12 items for ≥8 years of education), (3)
normal general cognitive functioning, measured by a
mini-mental state examination (MMSE) score of 24 or
higher, (4) a clinical dementia rating scale (CDR) of 0.5,
with at least a 0.5 in the memory domain, (5) normal or
minimal impairment in the activities of daily living
(ADL), a score of 20 to 26, and (6) absence of dementia,
or not sufficient to meet the National Institute of Neuro-
logical and Communicative Disorders and Stroke and
the Alzheimer's Disease and Related Disorders Associ-
ation (NINCDS-ADRDA) criteria for AD. Participants
were excluded if they had a past history of known stroke
(modified Hachinski score >4), alcoholism, head trauma,
Parkinson’s disease, epilepsy, major depression (excluded
by the self-rating depression scale) or any other neuro-
logical or psychiatric illness (excluded by clinical assess-
ment and case history), major medical illness (for
example, cancer, anemia, thyroid dysfunction), or severe
visual or hearing loss.
Control participants were required to have a CDR of
0, a MMSE score ≥26, and a delayed recall score >4 for
those with 8 or more years of education.
DNA isolation and SNP genotyping
Four milliliters of peripheral blood from each participant
was collected into EDTA-containing vacutainer tubes
and stored at −80°C. Genomic DNA was isolated using
the Wizard Genomic DNA purification Kit (Promega,
Madison, WI, USA) according to the manufacturer’s
protocol. The PCR primers were designed using Geno-
typing Tools (Sequenom, Hamburg, Germany) and Mas-
sARRAY Assay Design software (Sequenom) and were
synthesized by Invitrogen China (Beijing, China). PCR
amplification reactions (5 μl) were performed in stand-
ard 384-well plates using 10 ng genomic DNA, 0.5 U of
Taq polymerase (HotStarTaq, Qiagen, Valencia, CA,
USA), 0.1 μl of 25 mM each dNTP and 0.5 pmol of each
PCR primer. PCR thermal cycling was carried out for 4
min at 94°C, followed by 45 cycles of 20 s at 94°C, 30 s
at 56°C, 1 min at 72°C and then 3 min at 72°C. Next, 0.5
U of shrimp alkaline phosphatase (SAP; Sequenom) and
0.17 μl of buffer were added to the PCR reaction pro-
ducts and were incubated for 20 min at 37°C, then inac-
tivated for 5 min at 85°C to get rid of free dNTP. Post-
PCR reactions, also called single base extension (SBE)
reactions, which were performed in a final volume of 9
μl containing 0.804 μl of each Primer Mix, 0.041 μl of
iPLEX enzyme, and 0.2 μl of Terminator, and consisted
of 40 cycles of denaturation at 94°C and a final 3 min
extension step at 72°C. The products of the iPLEX reac-
tion were purified by 6 mg Clean Resin (Sequenom) and
were then spotted on a SpectroChip (Sequenom). Data
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were processed and analyzed by MassARRAY TYPER
4.0 software (Sequenom).
MRI scanning
All of the participants were scanned with a General Elec-
tric 1.5 Tesla scanner (General Electric Medical Systems,
Miwaukee, WI, USA) by two experienced doctors from
the radiology department following a standard imaging
protocol. The participants lay supine with their heads
snugly fixed by a belt and pads were used to minimize
head motion. Functional images (T2* weighted images)
were obtained using a GRE-EPI pulse sequence with the
following parameters: 30 contiguous axial slices, slice
thickness/gap = 4.0/0 mm, in-plane resolution = 3.75 ×
3.75 mm2, TR = 3000 ms, TE = 40 ms, flip angle = 90°,
acquisition matrix = 64 × 64, FOV = 240 × 240 mm.
This acquisition sequence generated 142 volumes in 7
min and 6 s. In addition, three-dimensional T1-weighted
axial images covering the whole brain were obtained
using a spoiled gradient echo (SPGR) sequence (TR =
9.9 ms, TE = 2.1 ms, slice thickness = 2.0 mm, gap = 0
mm, flip angle = 15°, FOV = 240 × 240 mm, acquisition
matrix = 256 × 192). Participants were instructed to
keep their eyes closed, bodies aplanatic and not to think
systematically or fall asleep during the scanning.
MRI data preprocessing
The first eight volumes of each functional time course
were discarded to allow for T1 equilibrium and to allow
the participants to adapt to the scanning conditions.
Slice timing, head motion correction, and spatial
normalization were conducted using SPM5 (http://www.
fil.ion.ucl.ac.uk/spm). Participants with head motion of
more than a 3.0 mm maximum displacement in any dir-
ection (x, y, and z) or 3.0° of angular motion throughout
the course of the scan were excluded from this study.
The resulting images were spatially smoothed (full width
at half maximum (FWHM) = 8 mm) using SPM 5. Then,
REST software (http://resting-fmri.sourceforge.net) was
used for linear trend removal temporal band-pass filter-
ing (0.01 ~ 0.08 Hz) [9,22].
ALFF calculation
ALFF was calculated using REST software similar to that
used in previous studies [17,23,24]. Briefly, for a given
voxel, after image preprocessing, the time series of re-
sultant images was first converted to the frequency do-
main using a Fast Fourier Transform and the power
spectrum was then acquired. The square root was com-
puted at each frequency of the power spectrum and
averaged between 0.01 and 0.08 Hz, and this averaged
square root was termed ALFF. For standardization, a
whole-brain mask was created by removing the back-
ground and other tissues outside the brain in the
anatomical images using MRIcro software (http://www.
mricro.com) [25-27].
Voxelwise-based gray matter volume correction
To control for possible differences in ALFF that may be
explained by differences in gray matter distribution be-
tween participants and to isolate the functional changes
in components that cannot be attributed to anatomical
differences, and thus are likely due to genuine functional
differences, our study adopted estimates of a voxel’s like-
lihood of containing gray matter as a covariate (nuisance
variable) in the analysis of the resting-state functional
data [28]. First, voxel-based morphometry (VBM)
[29,30] was used to explore gray matter volume maps of
each participant. Second, the maps were transformed
into the same standard space as the resting-state fMRI
images using affine linear registration [31]. Finally, these
resulting voxelwise gray matter volume maps were input
as covariates in the analysis of the functional data.
Voxelwise-based gray matter volume correction was
used for each participant. The ALFF corrected by the
voxelwise-based gray matter volume was then analyzed
as follows.
Statistical analysis
To determine the effects of group and genotype on
ALFF, we performed a two-way analysis of variance
(ANOVA) on a voxel-by-voxel basis with groups (aMCI
patients and healthy controls) and genotypes (CC, CT
and TT). To further explore the details of those clusters
showing significant main effects and interactions, post
hoc t tests were performed. All the statistical maps were
corrected for multiple comparisons using a significance
level of P value <0.05, based on Monte Carlo simulations
(parameters: single voxel P value = 0.05, a minimum
cluster size of 10503 mm3, FWHM = 8 mm, with mask.
See program AlphaSim by D. Ward, and http://afni.
nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf ). Fi-
nally, we performed a correlative analysis between the
neuropsychological test scores and the ALFF values of
the clusters showing significant interactions between
group and genotype (P <0.05).
Results
Neuropsychological data
The demographic and neuropsychological data for all
the participants are shown in Table 1. There were no
significant differences in gender, age, education levels
between the two groups. Compared with the controls,
the aMCI participants showed deficits in memory (audi-
tory verbal learning test delayed recall and Rey-
Osterrieth complex figure test delayed recall), construc-
tion (clock drawing test), attention/psychomotor speed
(trail making test A, symbol digit modalities and digit
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span test), and executive functions (trail making test B).
Further comparisons of the neuropsychological battery
between the three genotypes of aMCI patients showed
no significant differences, all P >0.05 (Table 2).
The influence of diseases × genotypes on ALFF
(1) Brain regions showing a significant main effect of
groups were identified in the frontal cortex (left inferior
gyrus), temporal cortex (left superior and middle lobes),
parietal cortex ((right precuneus (Pcu)), occipital cortex
(right calcarine) and cerebellar cortex (right posterior
lobe), while main effects of genotypes were found only
in the frontal cortex (bilateral middle, left inferior and
right superior gyri, right anterior cingulum). In particu-
lar, regions associated with an interaction of groups ×
genotypes were found in the parietal cortex (left Pcu),
frontal cortex (left superior, middle, and medial gyri,
right anterior cingulum), left middle occipital lobe and
the bilateral posterior lobes of the cerebellum (for details
see Table 3 and Figure 1).
The influence of factors on changes in ALFF
Post hoc test: a) Compared to the control group, the
aMCI group showed decreased ALFF in regions of the
dominant hemisphere, including in the left inferior
frontal gyrus and the left superior and middle temporal
lobe, while increased ALFF was shown in the right Pcu
and calcarine regions (Figure 2A). b) Compared to the
CT genotype, the CC genotype showed increased ALFF
in the left middle and inferior frontal gyri, and compared
to the TT genotype, the CC genotype also showed
increased ALFF in right medial and superior frontal gyri
and the right anterior cingulum, while there were no sig-
nificant differences between the CT and TT genotypes
(Figure 2B). c) Further analysis of the interactions be-
tween groups and genotypes revealed that in both the
aMCI and control groups, the CC genotype showed sig-
nificantly higher ALFF than the CT and TT genotypes.
In addition, we found that the ALFF value for each
genotype in the control group was higher than that of
the aMCI group, based on visual comparisons (no sig-
nificant difference in statistics) (Figure 2C).
Table 1 Demographic and neuropsychological data between aMCI group and healthy control group
Items aMCI group(n = 47) Control group(n = 33) P value
Gender (male: female) 28:19 18:15 0.654○
Age (years) 71.957 ± 4.777 72.848 ± 3.392 0.662△
Education levels (years) 15.894 ± 11.429 14.742 ± 2.889 0.124△
Clinical dementia rating (CDR) 0.5 0 —
Mini mental state exam (MMSE) 26.979 ± 1.525 28.182 ± 1.334 0.001*△
Auditory verbal learning test delayed recall 2.894 ± 1.747 7.970 ± 1.845 0.000*△
Rey-Osterrieth complex figure test delayed recall 10.787 ± 7.395 16.578 ± 7.009 0.002*△
Trail making test A (seconds) 94.404 ± 34.518 73.818 ± 29.591 0.006*△
Trail making test B (seconds) 189.447 ± 77.565 139.849 ± 43.953 0.003*△
Symbol digit modalities test 26.575 ± 9.930 34.000 ± 10.161 0.003*△
Clock drawing test 8.192 ± 1.676 9.000 ± 1.047 0.011*△
Digit span test 12.106 ± 2.119 13.091 ± 2.127 0.027*△
Note: data are presented as mean ± SD. *indicates had statistical difference between groups, P value <0.05. ○: The P value was obtained by Pearson chi-square
test. △: The P value was obtained by Mann–Whitney U test, which was used here due to the data not being normally distributed.
Table 2 Neuropsychological data between three genotype groups in aMCI patients
Items CC(n = 13) CT(n = 23) TT(n = 11) Chi-square P
mean rank
Mini-mental state exam (MMSE) 22.62 27.48 18.36 3.714 .156
Auditory verbal learning test delayed recall 26.00 21.33 27.23 1.863 .394
Rey-Osterrieth complex figure test delayed recall 26.58 21.74 25.68 1.254 .534
Trail making test A (seconds) 23.46 21.78 29.27 2.250 .325
Trail making test B (seconds) 20.15 24.85 26.77 1.561 .458
Symbol digit modalities test 24.00 25.48 20.91 .829 .661
Clock drawing test 20.50 26.43 23.05 1.747 .418
Digit span test 27.88 25.11 17.09 4.103 .129
Note: The P value was obtained by Kruskal-Wallis test (a type of nonparametric test) as the statistical test, as the data of the three groups were not normally
distributed.
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Correlations between ALFF values and behavioral scores
Correlations between the ALFF values of the clusters
showing significant interactions with the neuropsycho-
logical tests scores are shown in Figure 3. There was a
positive correlation in the left frontal cortex between
ALFF and behavioral tests in the memory domain in the
CC genotype, and a negative correlation in the right
frontal cortex between ALFF and MMSE in the CT
genotype, while in the TT genotype, we found a negative
correlation in the bilateral frontal cortex and a positive
correlation in the left posterior cerebellum between
ALFF and the nonmemory domains.
Discussion
In this imaging genetics analysis, we investigated for the
first time the effect of rs1143627 (−31 T > C) loci poly-
morphism of IL1B gene on brain regional spontaneous
activity in aged subjects presenting with aMCI and nor-
mally aging participants. We found that, among the CC,
CT, and TT genotypes, many brain regions showed sig-
nificant differences in ALFF between the aMCI patients
and the controls. Interestingly, we found that the regions
of interaction between the genotypes and the groups
showed some overlap with the default mode networks,
including the Pcu, the superior frontal gyrus, the anter-
ior cingulum cortex (ACC) and some other frontal
regions. Further behavioral significance suggested a role
for the rs1143627 polymorphism in regional neuronal
activity that has some effects on cognitive aging.
The protein IL-1β, encoded by a 7.5 kb gene with
seven exons, is regulated both by distal and proximal
promoter elements [32]. The promoter SNP locus
rs1143627 (−31 T > C) is located in a TATA-box motif,
which markedly affects DNA-protein interactions
in vitro [33], and the change from −31 T to -31C may
disrupt the TATA-box, leading to potential reduced or
abolished transcriptional activity of the promoter
[34,35].A genome-wide association study (GWAS) con-
firmed that −31 T > C had the highest LOD score, pro-
viding strong, unbiased evidence that this SNP is
functional and that IL-1β mRNA expression is a herit-
able trait [36].
It has been demonstrated both in vivo and in vitro that
basal IL-1β expression is involved in the physiological
long-term potentiation (LTP), a process believed to under-
lie certain forms of learning and memory [37]. At sufficient
Table 3 Groups × genotypes ANOVA of ALFF
Brain region BA Peak MNI coordinates (mm) Peak F value Cluster size
x y z
(1) Main effect of groups
L inferior frontal gyrus/superior temporal lobe/middle temporal lobe 22/38/45 −57 21 21 26.78 23841
R calcarine/precuneus/cerebellum posterior lobe 7/18 6 −63 −18 12.27 15120
(2) Main effect of genotypes
L middle frontal gyrus/inferior frontal gyrus 9/45 −57 21 18 19.53 13851
R medial frontal gyrus/superior frontal gyrus/ anterior cingulum 10 6 63 6 12.88 13608
(3) Groups × genotypes interaction
L superior frontal gyrus/middle frontal gyrus/ medial frontal gyrus/R
anterior cingulum
9/32/46 −54 27 21 13.14 19278
L middle occipital lobe/cuneus/precuneus 19 −21 −96 24 9.34 10557
B cerebellum posterior lobe — −24 −60 −24 8.56 18468
Note: a corrected threshold by Monte Carlo stimulation at P <0.05. Cluster size is in mm3. BA, Brodmann's area; B, bilateral; L, left; MNI. Montreal Neurological
Institute; R, right.
Figure 1 Groups × genotypes ANOVA of ALFF. Thresholds were set at a corrected P <0.05, determined by Monte Carlo stimulation.
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concentrations, IL-1β has an inhibitory effect on LTP in
many regions of the hippocampus [38]. Additionally, the
injection of lipopolysaccharide (LPS), a potent inducer of
IL-1β expression, into the CA1 regions of the rat hippo-
campus results in learning and memory deficits [39]. Post-
mortem brain tissue from patients with early-stage AD
showed significantly increased expression of caspase-1
(CASP1), also known as IL-1β converting enzyme (ICE)
[40]. A previous meta-analysis of cytokines found a signifi-
cantly higher concentration of IL-1β in the peripheral
blood of AD patients [6]. A case–control study on CSF
concluded that intrathecal inflammation precedes the de-
velopment of AD [41], and found the levels of IL-1β were
significantly correlated with the levels of tau and Aβ in
patients with MCI who had progressed to AD at the
follow-up nine months later. Furthermore, it was found
the IL-1β levels were correlated to MMSE at both baseline
and follow-up assessments. There have been many associ-
ating IL1B gene SNPs with the risk of occurrence of AD,
but the results are controversial (see http://www.alzgene.
org/). A previous genetic association study of Chinese par-
ticipants did not detect any genotypic or allelic frequency
differences in IL1B -31C/T between an AD group and a
control group, and concluded that the -31C/T polymorph-
ism was not a risk factor for AD [42], while the result
needs to be further confirmed.
Our study showed decreased ALFF in the inferior
frontal gyrus, the superior temporal lobe and the middle
Figure 2 Post hoc test. Thresholds were set at a corrected P <0.05, determined by Monte Carlo stimulation. (A) Compared with controls group,
aMCI group showed increased ALFF in right Pcu/calcarine, while decreased ALFF in left inferior frontal gyrus and superior/middle temporal lobe
(yellow: aMCI >control, blue: aMCI <control). (B) Compared with CT genotype, CC genotype showed increased ALFF in left middle/inferior frontal
gyrus, and compared with TT genotype, CC genotype also showed increased ALFF in right medial/superior frontal gyrus and right anterior
cingulum, while there were no significance between CT and TT genotype (yellow: CC >CT, blue: CC >TT). (C) Further analysis of interaction
between groups and genotypes found that both in aMCI and control groups, CC genotype showed significant higher ALFF than CT/TT genotype.
The ALFF value for each genotype in controls group was higher than that in aMCI group based on visual comparisons (no significant difference
in statistics). *P <0.05.
Figure 3 Correlations between ALFF and neuropsychological tests. Thresholds were set at a corrected P <0.05, determined by Monte Carlo
stimulation (yellow: positive correlation; blue: negative correlation).
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temporal lobe in aMCI patients, which was consistent
with previous hypoperfusion shown by SPECT and
hypometabolism shown by PET in aMCI/AD [43,44].
It is worth noting that the frontal and temporal lobes,
together with the parietal and occipital cortices, were
previously identified with more accumulation of 11C-
Pittsburgh compound B (PIB), consistent with brain
regions containing Aβ deposits [45]. A previous resting
state fMRI study also found that reductions in regional
activation [46,47], regional homogeneity [10,48] and
functional connectivity [49-52] were associated with
both AD and MCI patients. A recent combined struc-
tural and resting-state fMRI study [53] found broad
frontotemporal grey matter loss in MCI patients by
voxel-based morphometry (VBM) analysis, and found
regions of decreased connectivity to the posterior cingu-
lated cortex (PCC), which provides further support for
our findings. In the current study, we also observed
increased ALFF in the aMCI group, including in the oc-
cipital cortex (calcarine), parietal cortex (Pcu) and cere-
bellar cortex. Jia and colleagues [19] found increased
ALFF/fractional ALFF (fALFF) activity in aMCI patients
in several occipital regions, which is consistent with the
present study. A previous PET study [54] showed a sig-
nificant increase in metabolism in the occipital cortex in
aMCI brains. Researchers have also observed that base-
line aMCI patients have increased cerebellar ALFF com-
pared to controls [55]. Thus, our results of ALFF in
aMCI suggested that aMCI patients might have relatively
conserved spontaneous brain activity in these regions.
The increased ALFF in the Pcu of aMCI patients in this
study was in contrast to previous studies, which showed
a decrease in ALFF. A structural MRI study showed that
Pcu undergoes significant atrophy in MCI and mild AD
[56]. In addition, lower functional connectivity within
the default mode network (DMN) in the Pcu and PCC
was detected in AD patients by an independent compo-
nent analysis (ICA) [57]. The PCC and Pcu of aMCI
patients displayed decreased ALFF/fALFF in a recent
study [19]. We found similar results regarding Pcu in
the present study. A recent resting state fMRI study [58]
identified PCC and Pcu hyperfunctional connectivity at
baseline in aMCI subjects, and a substantial decrease in
these connections was evident at follow-up, compared to
matched controls. Additionally, Jones et al. [59] analyzed
task-free fMRI data with both ICA and seed-based ana-
lysis, identifying the posterior DMN as having a decline
in connectivity, while an increase in connectivity
was observed in the Pcu when atrophy correction
was applied. A previous study [60] demonstrated
that endogenous neuronal activity regulated the regional
concentration of interstitial fluid Aβ levels, which drive
local Aβ aggregation. It is uncertain whether some
regions with early increased regional neural activity and
hyperfunctional connectivity could be a mechanism of
compensation for AD pathology or represent a more
proximate event leading to cognitive dysfunction. In
summary, our results suggested that aMCI patients had
abnormal ALFF in their intrinsic brain activity.
In this study, we observed that the rs1143627 C/T
genotype had main effects on the frontal cortex, includ-
ing the superior, middle, inferior and medial frontal gyri,
and the ACC. SNPs in the IL1B gene were shown to
have effects on the responsiveness of the amygdala and
ACC to emotional stimulation in major depression [61].
Additional brain regions that had interactions with
groups were in the frontal, parietal and occipital cortices
and in the posterior lobe of the cerebellum. A recent
genetic neuroimaging study [62] detected the effect of
the IL1B gene on frontal cortex function in schizophre-
nia. A mammalian genome study identified IL1B gene
polymorphisms that modulated scrapie (a type of neuro-
degenerative disease) susceptibility in sheep and goats,
and found IL-1β expression in the cerebellum [63].
These studies supported our findings of the genetic
effects of rs1143627 on different brain regions. In
addition, the CC genotype showed significantly higher
ALFF values than the CT and TT genotypes in both
aMCI and control participants, and each genotype
showed different or completely opposite results in the
association between ALFF and cognitive scores. This
study did not find the frequency of the three genotypes
between groups, consistent with a previously mentioned
study [42]. We did not find any significant effects of the
genotypes on cognition in aMCI patients. This was not
in contradiction to the behavioral significance, as the
pathophysiological process of AD is thought to begin
many years, even decades, before the onset of clinical
dementia [64,65]. Thus, further large-scale association
replicated and longitudinal studies are needed.
There were biological and technical limitations to this
study that must be acknowledged. First, there was bio-
logical and clinical heterogeneity in the sample of aMCI
participants as recruitment was based only on clinical
criteria. Some participants may not display AD path-
ology, contaminating the sample with non-AD cases.
The heterogeneity could be minimized through a com-
bination of CSF and PET biomarkers. Second, as a result
of the limitation of the sample size, further adjustment
for multiple testing outside the domain of imaging
will be necessary and replication in independent samples
is also required to further establish the gene-imaging
phenotype association. Third, previous resting state
fMRI studies [66,67] have demonstrated very moderate
test-retest reliability based on Monte Carlo simulations
and, because calculation methods will be improved with
time, new analysis methods could be applied to future
studies.
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Conclusions
In this study, we provide evidence that aMCI patients
had abnormal ALFF in many brain regions, including in
the Pcu, the calcarine, the inferior frontal gyrus and the
superior and middle temporal lobe. In particular, we
showed that the rs1143627 C/T polymorphism might
have an effect on spontaneous regional brain activity in
aMCI patients.
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